PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.
[OBJECTIVES] Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge.
- p-value p < 0.01
APA
Woo S, Becker AS, et al. (2025). PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.. European radiology, 35(9), 5337-5347. https://doi.org/10.1007/s00330-025-11514-3
MLA
Woo S, et al.. "PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.." European radiology, vol. 35, no. 9, 2025, pp. 5337-5347.
PMID
40108014
Abstract
[OBJECTIVES] Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge. This study investigated clinicopathological and imaging findings that predict metastatic etiology of PSMA-avid rib lesions.
[MATERIALS AND METHODS] Consecutive patients with prostate cancer that underwent PET/CT with [F]F-DCFPyL in 2021-2023 for newly diagnosed intermediate-/high-risk prostate cancer or recurrent/metastatic disease and had PSMA-avid rib lesions were included. Imaging findings assessed were: lesion number, PSMA expression (maximum standard uptake value (SUV), miPSMA score), CT features (sclerotic, lucent, fracture, no correlate), other sites of metastases, and primary tumor findings. A composite reference standard for rib lesion etiology (metastatic vs non-metastatic) based on histopathology, serial imaging, and clinical assessment was used.
[RESULTS] One hundred and seventy-five men (median 71 years, IQR 65-77) with PSMA-avid rib lesions were included; 47/175 (26.9%) had rib metastases. Only 1/47 (2.1%) of these patients had isolated rib metastasis without PSMA-avid metastases in other bones, nodes, or visceral organs; the other 46/47 (97.9%) patients with rib metastases also had other sites of PSMA-avid disease. Patients with rib metastases were older, had higher prostate-specific antigen levels, and higher-grade tumors (p < 0.01). Metastatic rib lesions had higher uptake (SUV, miPSMA), more commonly involved multiple ribs, and were more often sclerotic (p < 0.01); lucency/fractures were only seen in benign lesions.
[CONCLUSION] Several imaging and clinicopathological factors differed between PSMA-avid metastatic and benign lesions. Isolated rib lesions without other sites of metastasis are almost always benign. Careful assessment of CT features can help diagnose benign lesions.
[KEY POINTS] Question While prostate-specific membrane antigen (PSMA)-PET/CT has become integral to the management of prostate cancer, PSMA-avid rib lesions pose a diagnostic challenge. Findings Approximately a quarter of patients who had PSMA-avid rib lesions were metastatic. However, only 2.1% of them had isolated rib metastasis (without PSMA-avid metastases elsewhere). Clinical relevance Isolated PSMA-avid rib lesions are almost always benign when there is no evidence of metastatic disease elsewhere. Scrutinizing CT features can help diagnose benign PSMA-avid lesions with greater certainty.
[MATERIALS AND METHODS] Consecutive patients with prostate cancer that underwent PET/CT with [F]F-DCFPyL in 2021-2023 for newly diagnosed intermediate-/high-risk prostate cancer or recurrent/metastatic disease and had PSMA-avid rib lesions were included. Imaging findings assessed were: lesion number, PSMA expression (maximum standard uptake value (SUV), miPSMA score), CT features (sclerotic, lucent, fracture, no correlate), other sites of metastases, and primary tumor findings. A composite reference standard for rib lesion etiology (metastatic vs non-metastatic) based on histopathology, serial imaging, and clinical assessment was used.
[RESULTS] One hundred and seventy-five men (median 71 years, IQR 65-77) with PSMA-avid rib lesions were included; 47/175 (26.9%) had rib metastases. Only 1/47 (2.1%) of these patients had isolated rib metastasis without PSMA-avid metastases in other bones, nodes, or visceral organs; the other 46/47 (97.9%) patients with rib metastases also had other sites of PSMA-avid disease. Patients with rib metastases were older, had higher prostate-specific antigen levels, and higher-grade tumors (p < 0.01). Metastatic rib lesions had higher uptake (SUV, miPSMA), more commonly involved multiple ribs, and were more often sclerotic (p < 0.01); lucency/fractures were only seen in benign lesions.
[CONCLUSION] Several imaging and clinicopathological factors differed between PSMA-avid metastatic and benign lesions. Isolated rib lesions without other sites of metastasis are almost always benign. Careful assessment of CT features can help diagnose benign lesions.
[KEY POINTS] Question While prostate-specific membrane antigen (PSMA)-PET/CT has become integral to the management of prostate cancer, PSMA-avid rib lesions pose a diagnostic challenge. Findings Approximately a quarter of patients who had PSMA-avid rib lesions were metastatic. However, only 2.1% of them had isolated rib metastasis (without PSMA-avid metastases elsewhere). Clinical relevance Isolated PSMA-avid rib lesions are almost always benign when there is no evidence of metastatic disease elsewhere. Scrutinizing CT features can help diagnose benign PSMA-avid lesions with greater certainty.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Aged; Positron Emission Tomography Computed Tomography; Glutamate Carboxypeptidase II; Bone Neoplasms; Diagnosis, Differential; Ribs; False Positive Reactions; Antigens, Surface; Radiopharmaceuticals; Retrospective Studies; Urea; Lysine
같은 제1저자의 인용 많은 논문 (5)
- ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.
- Identification of Key Anatomic Structures on Magnetic Resonance Imaging During Prostate Stereotactic Body Radiation Therapy for Dose Avoidance to Reduce Erectile Dysfunction Risk.
- Multiparametric MRI assessment of 6-month Post-Treatment response following Real-Time adaptive stereotactic body radiotherapy for prostate cancer: Correlation with Post-Treatment PSA kinetics.
- Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era.
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.